A detailed history of Dynamic Technology Lab Private LTD transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 17,366 shares of PBYI stock, worth $52,792. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,366
Holding current value
$52,792
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.25 - $4.03 $39,073 - $69,984
17,366 New
17,366 $44,000
Q3 2021

Nov 15, 2021

SELL
$6.63 - $9.39 $125,830 - $178,212
-18,979 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$8.98 - $11.6 $65,751 - $84,935
7,322 Added 62.81%
18,979 $174,000
Q1 2021

May 14, 2021

BUY
$9.38 - $13.63 $109,342 - $158,884
11,657 New
11,657 $113,000
Q4 2020

Feb 11, 2021

SELL
$7.78 - $12.13 $109,884 - $171,324
-14,124 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$9.5 - $11.14 $134,178 - $157,341
14,124 New
14,124 $143,000
Q2 2020

Aug 14, 2020

SELL
$7.01 - $13.24 $236,454 - $446,598
-33,731 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$6.28 - $14.57 $24,410 - $56,633
3,887 Added 13.02%
33,731 $285,000
Q4 2019

Feb 14, 2020

BUY
$6.5 - $10.73 $43,075 - $71,107
6,627 Added 28.54%
29,844 $261,000
Q3 2019

Nov 14, 2019

BUY
$8.75 - $12.85 $203,148 - $298,338
23,217 New
23,217 $250,000
Q2 2019

Aug 14, 2019

SELL
$12.3 - $35.76 $109,728 - $319,014
-8,921 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$20.77 - $42.37 $135,191 - $275,786
-6,509 Reduced 42.18%
8,921 $346,000
Q4 2018

Feb 13, 2019

BUY
$20.07 - $46.7 $309,680 - $720,581
15,430 New
15,430 $314,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $138M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.